Biosynth, a supplier of raw materials to the life sciences industry, recently acquired Celares, a developer and manufacturer of bioconjugate drugs, conjugate vaccines, activated PEGs and polymer-based drug delivery excipients.
 
With this acquisition Biosynth aims to strengthen its exposure to that fast-growing bioconjugate and conjugate vaccines markets. This expands the company’s capabilities and enables Biosynth to offer the bioconjugation of antibodies, antigens and peptides to existing pharma and diagnostics customers from GMP facilities in Berlin, Germany. 
 
“Celares is an established leader in bioconjugation, and we are extremely excited to be acquiring such a great team of specialists. Celares is a perfect complement to our wider business, enabling us to provide bioconjugation services and the production of PEGylation reagents and polymers for drug delivery. Together, we can support customers form development to commercialization. Celares is a perfect fit for Biosynth – where chemistry meets biology,” said Biosythn President and CEO Urs Spitz.
 
Managing director of Celares, Ralf Kraehmer commented, “We are thrilled to have joined the Biosynth group. As established leaders in bioconjugation, Celares combines decades of chemical and biotechnological experience within the company and offers customers the possibility to access forward-looking technologies. Optimal polymer-based conjugations and formulations and manufacturing processes of drug compounds is part of our development. We see great similarities in Biosynth with their customer led strategy and passion for the life science industry.”